Regeneron Pharmaceuticals (REGN) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.Sale George L. Sing, Director sold 1,000 shares at $960.26 ($960K).
- Trade date
- Nov 16, 2026
- Disclosed to the SEC
- Nov 18, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All REGN insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
REGN insider transactions (Form 4)
Open-market purchases and sales. 73 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 18SEC | George L. SingDirector | Sell | 1,00024,147 held (−4%) | $960.26 | $960K | -2.9% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 67150,434 held (−1%) | $953.69 | $640K | -2.2% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 58447,669 held (−1%) | $961.45 | $561K | -3.0% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 50648,510 held (−1%) | $959.45 | $485K | -2.8% | — |
| Nov 18SEC | George L. SingDirector | Sell | 46523,147 held (−2%) | $958.11 | $446K | -2.7% | — |
| Nov 18SEC | George L. SingDirector | Sell | 35923,612 held (−1%) | $957.49 | $344K | -2.6% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 34649,462 held (−1%) | $956.70 | $331K | -2.5% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 34046,779 held (−1%) | $964.36 | $328K | -3.3% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 31349,808 held (−1%) | $955.48 | $299K | -2.4% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 31350,121 held (−1%) | $954.45 | $299K | -2.3% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 29547,374 held (−1%) | $962.70 | $284K | -3.1% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 29851,325 held (−1%) | $951.75 | $284K | -2.0% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 25748,253 held (−1%) | $960.65 | $247K | -2.9% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 25547,119 held (−1%) | $963.60 | $246K | -3.2% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 24449,016 held (−0%) | $958.27 | $234K | -2.7% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 22051,105 held (−0%) | $952.75 | $210K | -2.1% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 20249,260 held (−0%) | $957.53 | $193K | -2.6% | — |
| Nov 18SEC | George L. SingDirector | Sell | 17623,971 held (−1%) | $956.96 | $168K | -2.6% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 9351,697 held (−0%) | $949.69 | $88K | -1.8% | — |
| Nov 18SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 7451,623 held (−0%) | $950.61 | $70K | -1.9% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 6610,606 held (−1%) | $959.46 | $63K | -2.8% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 6310,331 held (−1%) | $965.62 | $61K | -3.4% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 5910,498 held (−1%) | $961.36 | $57K | -3.0% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 5910,768 held (−1%) | $954.46 | $56K | -2.3% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 4910,557 held (−0%) | $960.31 | $47K | -2.9% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 4410,672 held (−0%) | $958.47 | $42K | -2.7% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 4410,827 held (−0%) | $952.79 | $42K | -2.1% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 4210,415 held (−0%) | $963.70 | $40K | -3.2% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 4110,457 held (−0%) | $962.44 | $39K | -3.1% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 3010,738 held (−0%) | $955.51 | $29K | -2.4% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 2610,305 held (−0%) | $971.93 | $25K | -4.1% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 2210,716 held (−0%) | $956.01 | $21K | -2.5% | — |
| Nov 18SEC | Marion McCourtEvp Commercial | Sell Plan | 2110,394 held (−0%) | $964.69 | $20K | -3.3% | — |
| Nov 6SEC | Jason PitofskySvp Controller | Sell | 1,2154,944 held (−20%) | $942.31 | $1.1M | -1.0% | — |
| Nov 6SEC | Jason PitofskySvp Controller | Sell | 9826,159 held (−14%) | $941.58 | $925K | -1.0% | — |
| Nov 6SEC | Jason PitofskySvp Controller | Sell | 5757,141 held (−7%) | $940.46 | $541K | -0.8% | — |
| Nov 6SEC | Jason PitofskySvp Controller | Sell | 5294,415 held (−11%) | $943.53 | $499K | -1.2% | — |
| Nov 6SEC | Jason PitofskySvp Controller | Sell | 4397,716 held (−5%) | $939.57 | $412K | -0.7% | — |
| Nov 6SEC | Jason PitofskySvp Controller | Sell | 179 | $950.76 | $170K | -1.9% | — |
| Nov 6SEC | Jason PitofskySvp Controller | Sell | 1084,307 held (−2%) | $944.22 | $102K | -1.2% | — |
| Nov 6SEC | Jason PitofskySvp Controller | Sell | 354,272 held (−1%) | $945.61 | $33K | -1.4% | — |
| Nov 5SEC | Huda Y. ZoghbiDirector | Sell | 6,9392,203 held (−76%) | $970.42 | $6.7M | -3.9% | — |
| Nov 5SEC | Huda Y. ZoghbiDirector | Sell | 5001,703 held (−23%) | $971.06 | $486K | -4.0% | — |
| Nov 4SEC | George L. SingDirector | Sell | 7,07327,909 held (−20%) | $965.38 | $6.8M | -3.4% | — |
| Nov 4SEC | George L. SingDirector | Sell | 4,33837,652 held (−10%) | $963.47 | $4.2M | -3.2% | — |
| Nov 4SEC | Joseph J. LarosaGeneral Counsel | Sell | 3,93939,433 held (−9%) | $965.41 | $3.8M | -3.4% | — |
| Nov 4SEC | Christine A. PoonDirector | Sell | 3,2036,357 held (−34%) | $969.50 | $3.1M | -3.8% | — |
| Nov 4SEC | George L. SingDirector | Sell | 2,67034,982 held (−7%) | $964.57 | $2.6M | -3.3% | — |
| Nov 4SEC | George L. SingDirector | Sell | 2,52241,990 held (−6%) | $962.61 | $2.4M | -3.1% | — |
| Nov 4SEC | Christine A. PoonDirector | Sell | 2,4999,560 held (−21%) | $968.58 | $2.4M | -3.7% | — |
| Nov 4SEC | George L. SingDirector | Sell | 1,52226,387 held (−5%) | $966.27 | $1.5M | -3.5% | — |
| Nov 4SEC | George L. SingDirector | Sell | 1,22445,052 held (−3%) | $960.57 | $1.2M | -2.9% | — |
| Nov 4SEC | George L. SingDirector | Sell | 1,04025,347 held (−4%) | $967.07 | $1.0M | -3.6% | — |
| Nov 4SEC | Christine A. PoonDirector | Sell | 9375,420 held (−15%) | $970.51 | $909K | -3.9% | — |
| Nov 4SEC | Christine A. PoonDirector | Sell | 77212,059 held (−6%) | $967.38 | $747K | -3.6% | — |
| Nov 4SEC | George L. SingDirector | Sell | 54044,512 held (−1%) | $961.85 | $519K | -3.0% | — |
| Nov 4SEC | Joseph J. LarosaGeneral Counsel | Sell | 52738,906 held (−1%) | $966.11 | $509K | -3.5% | — |
| Nov 4SEC | Christine A. PoonDirector | Sell | 21812,831 held (−2%) | $966.74 | $211K | -3.5% | — |
| Nov 4SEC | Christine A. PoonDirector | Sell | 2015,219 held (−4%) | $971.31 | $195K | -4.0% | — |
| Nov 4SEC | George L. SingDirector | Sell | 20025,147 held (−1%) | $970.18 | $194K | -3.9% | — |
| Nov 3SEC | Michael S. BrownDirector | Sell Plan | 1,9291,380 held (−58%) | $875.00 | $1.7M | +6.6% | — |
| Nov 3SEC | Marion McCourtEvp Commercial | Sell Plan | 1,13210,871 held (−9%) | $869.43 | $984K | +7.3% | — |
| Nov 3SEC | Kathryn GuariniDirector | Sell Plan | 400603 held (−40%) | $900.00 | $360K | +3.6% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 46347,883 held (−1%) | $780.63 | $361K | +19.5% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 45448,726 held (−1%) | $778.64 | $354K | +19.8% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 38048,346 held (−1%) | $779.59 | $296K | +19.6% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 37649,284 held (−1%) | $775.46 | $292K | +20.3% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 28350,216 held (−1%) | $771.56 | $218K | +20.9% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 27950,935 held (−1%) | $766.47 | $214K | +21.7% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 27151,214 held (−1%) | $765.39 | $207K | +21.8% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 22449,781 held (−0%) | $773.40 | $173K | +20.6% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 21951,485 held (−0%) | $764.40 | $167K | +22.0% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 21150,005 held (−0%) | $772.56 | $163K | +20.7% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 19250,743 held (−0%) | $767.39 | $147K | +21.5% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 12750,511 held (−0%) | $769.30 | $98K | +21.2% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 12149,660 held (−0%) | $774.48 | $94K | +20.4% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 10550,638 held (−0%) | $768.33 | $81K | +21.4% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 7451,811 held (−0%) | $760.65 | $56K | +22.6% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 6649,218 held (−0%) | $776.31 | $51K | +20.1% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 5551,729 held (−0%) | $762.57 | $42K | +22.3% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 5047,833 held (−0%) | $781.47 | $39K | +19.3% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 3849,180 held (−0%) | $777.76 | $30K | +19.9% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 3551,939 held (−0%) | $755.91 | $26K | +23.4% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 2751,784 held (−0%) | $761.36 | $21K | +22.5% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 2551,704 held (−0%) | $763.76 | $19K | +22.1% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 2451,899 held (−0%) | $758.16 | $18K | +23.0% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 1651,923 held (−0%) | $757.68 | $12K | +23.1% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 1451,885 held (−0%) | $759.96 | $11K | +22.7% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 1250,499 held (−0%) | $770.20 | $9K | +21.1% | — |
| Oct 15SEC | Andrew J. MurphyCo-Chief Scientific Officer | Sell Plan | 651,974 held (−0%) | $753.76 | $5K | +23.7% | — |
| Sep 3SEC | Marion McCourtEvp Commercial | Sell Plan | 1,21513,134 held (−8%) | $850.00 | $1.0M | +9.7% | — |
| Sep 3SEC | Marion McCourtEvp Commercial | Sell Plan | 1,13112,003 held (−9%) | $857.39 | $970K | +8.8% | — |
| Sep 3SEC | Kathryn GuariniDirector | Sell Plan | 400603 held (−40%) | $850.00 | $340K | +9.7% | — |
| Aug 12SEC | Huda Y. ZoghbiDirector | Sell Plan | 8001,703 held (−32%) | $800.00 | $640K | +16.6% | — |
| Aug 12SEC | Kathryn GuariniDirector | Sell Plan | 400603 held (−40%) | $800.00 | $320K | +16.6% | — |
| Jul 7SEC | Arthur F. RyanDirector | Sell Plan | 20017,303 held (−1%) | $650.15 | $130K | +43.4% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 2417,559 held (−0%) | $703.46 | $17K | +32.6% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 1517,544 held (−0%) | $704.28 | $11K | +32.4% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 1517,583 held (−0%) | $702.46 | $11K | +32.8% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 1417,530 held (−0%) | $705.56 | $10K | +32.2% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 717,523 held (−0%) | $706.74 | $5K | +31.9% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 617,513 held (−0%) | $709.45 | $4K | +31.4% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 517,506 held (−0%) | $711.49 | $4K | +31.1% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 517,598 held (−0%) | $701.76 | $4K | +32.9% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 417,519 held (−0%) | $707.40 | $3K | +31.8% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 217,503 held (−0%) | $714.13 | $1K | +30.6% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 217,511 held (−0%) | $710.87 | $1K | +31.2% | — |
| May 4SEC | Arthur F. RyanDirector | Sell Plan | 117,505 held (−0%) | $712.09 | $712 | +31.0% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 4017,603 held (−0%) | $779.71 | $31K | +19.6% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 1417,669 held (−0%) | $775.58 | $11K | +20.2% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 1317,656 held (−0%) | $776.62 | $10K | +20.1% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 917,647 held (−0%) | $777.42 | $7K | +20.0% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 817,683 held (−0%) | $774.58 | $6K | +20.4% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 817,691 held (−0%) | $773.59 | $6K | +20.5% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 417,643 held (−0%) | $778.24 | $3K | +19.8% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 317,699 held (−0%) | $772.76 | $2K | +20.7% | — |
| Apr 3SEC | Arthur F. RyanDirector | Sell Plan | 117,702 held (−0%) | $771.32 | $771 | +20.9% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 2017,703 held (−0%) | $789.28 | $16K | +18.2% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 2017,723 held (−0%) | $788.96 | $16K | +18.2% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 1117,752 held (−0%) | $785.48 | $9K | +18.7% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 1017,772 held (−0%) | $783.62 | $8K | +19.0% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 917,763 held (−0%) | $784.48 | $7K | +18.9% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 717,745 held (−0%) | $786.61 | $6K | +18.6% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 717,796 held (−0%) | $777.46 | $5K | +19.9% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 517,789 held (−0%) | $779.69 | $4K | +19.6% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 317,786 held (−0%) | $780.69 | $2K | +19.5% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 217,743 held (−0%) | $787.34 | $2K | +18.4% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 217,782 held (−0%) | $782.62 | $2K | +19.2% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 217,784 held (−0%) | $781.21 | $2K | +19.4% | — |
| Mar 3SEC | Arthur F. RyanDirector | Sell Plan | 217,794 held (−0%) | $778.30 | $2K | +19.8% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 3312,650 held (−11%) | $780.45 | $258K | +19.5% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 2982,143 held (−12%) | $782.10 | $233K | +19.2% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 2201,923 held (−10%) | $783.29 | $172K | +19.1% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 2092,441 held (−8%) | $781.28 | $163K | +19.4% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 2082,981 held (−7%) | $779.55 | $162K | +19.6% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 1601,763 held (−8%) | $784.45 | $126K | +18.9% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 561,707 held (−3%) | $785.61 | $44K | +18.7% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 533,189 held (−2%) | $778.47 | $41K | +19.8% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 503,242 held (−2%) | $775.50 | $39K | +20.2% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 493,292 held (−1%) | $774.68 | $38K | +20.4% | — |
| Feb 23SEC | Huda Y. ZoghbiDirector | Sell Plan | 41,703 held (−0%) | $790.00 | $3K | +18.0% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 5634,813 held (−10%) | $778.35 | $438K | +19.8% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 5215,767 held (−8%) | $776.43 | $405K | +20.1% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 3915,376 held (−7%) | $777.51 | $304K | +19.9% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 2054,608 held (−4%) | $779.56 | $160K | +19.6% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 1444,326 held (−3%) | $783.23 | $113K | +19.1% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 754,533 held (−2%) | $780.06 | $59K | +19.5% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 5717,835 held (−0%) | $777.56 | $44K | +19.9% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 534,272 held (−1%) | $785.72 | $42K | +18.7% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 374,470 held (−1%) | $782.67 | $29K | +19.1% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 264,507 held (−1%) | $781.37 | $20K | +19.3% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 206,288 held (−0%) | $775.95 | $16K | +20.2% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 1217,823 held (−0%) | $778.53 | $9K | +19.8% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 1017,892 held (−0%) | $776.59 | $8K | +20.1% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 517,812 held (−0%) | $781.48 | $4K | +19.3% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 517,818 held (−0%) | $779.41 | $4K | +19.6% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 317,808 held (−0%) | $783.34 | $2K | +19.0% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 217,804 held (−0%) | $786.29 | $2K | +18.6% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 117,803 held (−0%) | $787.82 | $788 | +18.4% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 117,806 held (−0%) | $785.71 | $786 | +18.7% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 14,325 held (−0%) | $784.66 | $785 | +18.8% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 117,807 held (−0%) | $784.59 | $785 | +18.9% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 117,811 held (−0%) | $782.53 | $783 | +19.2% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 117,817 held (−0%) | $780.09 | $780 | +19.5% | — |
| Feb 11SEC | Arthur F. RyanDirector | Sell Plan | 117,902 held (−0%) | $775.63 | $776 | +20.2% | — |
| Jan 8SEC | Bonnie L. BasslerDirector | Sell Plan | 1,5001,703 held (−47%) | $800.00 | $1.2M | +16.6% | — |
| Nov 24SEC | Bonnie L. BasslerDirector | Sell Plan | 7601,548 held (−33%) | $750.00 | $570K | +24.3% | — |
| Nov 10SEC | Jason PitofskyVp Controller | Sell | 4314,233 held (−9%) | $651.43 | $281K | +43.2% | — |
| Oct 31SEC | Christine A. PoonDirector | Sell | 2,7355,467 held (−33%) | $653.50 | $1.8M | +42.7% | — |
| Oct 31SEC | Christine A. PoonDirector | Sell | 1,9153,552 held (−35%) | $654.42 | $1.3M | +42.5% | — |
| Oct 31SEC | Christine A. PoonDirector | Sell | 7122,740 held (−21%) | $656.50 | $467K | +42.0% | — |
| Oct 31SEC | Christine A. PoonDirector | Sell | 6508,202 held (−7%) | $652.68 | $424K | +42.9% | — |
| Oct 31SEC | Christine A. PoonDirector | Sell | 3882,352 held (−14%) | $657.29 | $255K | +41.9% | — |
| Oct 31SEC | Christine A. PoonDirector | Sell | 1003,452 held (−3%) | $655.10 | $66K | +42.4% | — |
Similar past setups: not applicable. REGN has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with REGN in the Research Lab
REGN has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Regeneron Pharmaceuticals insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 11 sold $65.2M of REGN stock on the open market; P/E 21.0 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
REGN insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $56.8M | 90 |
| Q3 2026 | — | 0 | $3.4M | 6 |
| Q2 2026 | — | 0 | $148K | 21 |
| Q1 2026 | — | 0 | $4.2M | 49 |
| Q4 2025 | — | 0 | $5.1M | 8 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Regeneron Pharmaceuticals insiders reported open-market purchases totaling $0, while 11 insiders reported sales totaling $65.2M. 136 of 174 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
REGN earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 6, 2026 | -7.4% | None | +2.2%S&P +0.3% | +21.9% |
| Jul 30, 2026 | +6.0% | Sold $130K | +9.7%S&P +2.4% | +4.3% |
| Jul 6, 2026 | +7.6% | Sold $130K | +3.4%S&P +0.4% | +14.2% |
| Apr 29, 2026 | -2.0% | Sold $78K | -3.4%S&P +1.0% | -12.9% |
| Apr 8, 2026 | +3.2% | Sold $78K | +1.0%S&P +3.1% | -6.9% |
| Jan 30, 2026 | -0.6% | Sold $1.2M | +0.7%S&P +0.2% | +4.4% |
| Jan 12, 2026 | +1.6% | Sold $1.2M | -4.7%S&P -0.0% | +3.3% |
| Oct 28, 2025 | +3.7% | None | +11.5%S&P +0.3% | +19.6% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
REGN short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded REGN
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +26.7% |
Insiders at Regeneron Pharmaceuticals
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| George L. SingDirector | — | $22.3M | Nov 18, 2026 | — | — |
| Christine A. PoonDirector | — | $11.8M | Nov 4, 2026 | — | — |
| Huda Y. ZoghbiDirector | — | $9.1M | Nov 5, 2026 | — | — |
| Andrew J. MurphyCo-Chief Scientific Officer | — | $8.0M | Nov 18, 2026 | — | — |
| Jason PitofskySvp Controller | — | $5.7M | Nov 6, 2026 | — | — |
| Joseph J. LarosaGeneral Counsel | — | $4.3M | Nov 4, 2026 | — | — |
| Marion McCourtEvp Commercial | — | $3.5M | Nov 18, 2026 | — | — |
| Bonnie L. BasslerDirector | — | $1.8M | Jan 8, 2026 | — | — |
| Michael S. BrownDirector | — | $1.7M | Nov 3, 2026 | — | — |
| Kathryn GuariniDirector | — | $1.0M | Nov 3, 2026 | — | — |
| Arthur F. RyanDirector | — | $435K | Jul 7, 2026 | — | — |
| Christopher R. FenimoreCFO | — | — | Nov 4, 2026 | — | — |
| N. Anthony ColesDirector | — | — | Jan 6, 2026 | — | — |
| Joseph L. GoldsteinDirector | — | — | Jan 6, 2026 | — | — |
| Craig B. ThompsonDirector | — | — | Jan 6, 2026 | — | — |
| David P. SchenkeinDirector | — | — | Jan 6, 2026 | — | — |
| Leonard S. SchleiferCEO, President | — | — | Jan 5, 2026 | — | — |
| George YancopoulosPresident, Chair | — | — | Jan 5, 2026 | — | — |
| Plew Daniel P. VanEvp & General Mgr, Industrial | — | — | Dec 11, 2025 | — | — |
Board links: companies that share insiders with REGN
Directors and executives who filed Form 4s for REGN and another company in the last 12 months.
- CRLCharles River Laboratories Craig B. Thompson Director here · Director at CRL · latest filing May 12, 2026
- PRUPrudential Financial Christine A. Poon Director here · Director at PRU · latest filing Nov 4, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
REGN stock: common questions
Are Regeneron Pharmaceuticals insiders buying REGN stock?
No. No Regeneron Pharmaceuticals insider reported an open-market purchase of REGN in the past 12 months.
Are Regeneron Pharmaceuticals insiders selling REGN stock?
11 insiders reported sales worth $65.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is REGN's P/E ratio?
REGN trades at about 21.0 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is REGN's 52-week range?
Over the past year REGN has traded between $599.96 and $973.36. It last closed at $932.53 on Nov 19, 2026.